Continue reading this on our app for a better experience

Open in App
Home News Covid-19

BioNTech says its Covid vaccine revenue may be lower this year

Bloomberg
Bloomberg • 1 min read
BioNTech says its Covid vaccine revenue may be lower this year
It is still not clear how many countries will pursue yet another round of shots later in the year.
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

BioNTech SE said its revenue from the Covid-19 shot it sells together with Pfizer Inc. may be lower this year than last, predicting sales between 13 billion euros ($19.94 billion; US$14.7 billion) and 17 billion euros.

The company said Covid vaccine sales last year will total 16 billion euros to 17 billion euros. It issued the 2022 prediction in an investor presentation on Tuesday and is due to release fourth-quarter financial data on March 30.

Pfizer in December forecast vaccine sales of US$31 billion this year, based on contracts for 1.9 billion doses signed through mid-November. The revenue is shared between the partners. The wave of infections due to the highly transmissible omicron variant has intensified booster campaigns in Europe and the U.S., though it’s still not clear how many countries will pursue yet another round of shots later in the year.

BioNTech rose 0.7% in Frankfurt after initially dipping on the news.

On Monday, Covid vaccine competitor Moderna Inc. said it had signed purchase agreements worth US$18.5 billion for this year, along with options for another US$3.5 billion.

Photo: Bloomberg

×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.